Sativex
Phase 3Small molecule
Jazz PharmaceuticalsSativex is one of 262 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.
8
Indications
40
Total Trials
0
Active Trials
261
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Sativex
Jazz PharmaceuticalsPhase 3
Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Avonex
EMD SeronoPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Zinbryta
RochePreclinical
Flomax
SanofiPreclinical
Novantrone
PfizerPreclinical
Myfortic
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Multiple Sclerosis10 trials
Show 7 more trials
Neuropathic Pain6 trials
Show 3 more trials
Glioblastoma2 trials
Single Dose2 trials
18 more indications
Cancer1 trial
Advanced Cancer1 trial
Older Patients1 trial
Hepatic Function1 trial
End-Stage Renal Disease1 trial
Spasticity1 trial
Tics1 trial
Memory1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sativex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company